Regeneron Pharmaceuticals Inc. buy Wells Fargo & Company
Start price
02.08.24
/
50%
€992.60
Target price
02.08.25
€1,099.3
Performance (%)
-51.42%
End price
03.08.25
€482.20
Summary
This prediction ended on 03.08.25 with a price of €482.20. Massive losses of -51.42% were the result for the BUY prediction by Wells_Fargo___Compan. Dividends of €1.72 are taken into consideration when calculating the performance. Wells_Fargo___Compan has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.787% | -0.787% | 17.068% |
| iShares Core DAX® | 1,16 % | 3,68 % | 4,55 % |
| iShares Nasdaq 100 | 2,59 % | 3,10 % | 36,50 % |
| iShares Nikkei 225® | 7,11 % | 10,60 % | 61,22 % |
| iShares S&P 500 | 1,26 % | 1,67 % | 25,23 % |
Comments by Wells_Fargo___Compan for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Wells Fargo & Company from $1,125.00 to $1,200.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von Wells_Fargo___Compan gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€519.00
30.04.25
30.04.25
€615.65
30.04.26
30.04.26
14.70%
01.05.26
01.05.26
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€693.60
10.01.25
10.01.25
€875.97
10.01.26
10.01.26
-1.53%
11.01.26
11.01.26
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€995.60
23.09.24
23.09.24
€1,078.7
23.09.25
23.09.25
-51.79%
24.09.25
24.09.25